CRDF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cardiff Oncology Inc (CRDF) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While there are some positive developments, such as encouraging clinical trial progress and analyst optimism, the company's financial performance, lack of significant trading signals, and long timeline for potential drug approval suggest a more cautious approach is warranted. Holding the stock or waiting for further developments may be more prudent.
The MACD histogram is positive at 0.0754 and expanding, indicating bullish momentum. The RSI is at 77.448, which is neutral but leaning toward overbought territory. Moving averages are converging, suggesting indecision in price direction. Key resistance levels are R1: 1.944 and R2: 2.063, while support levels are S1: 1.558 and S2: 1.439.
Encouraging clinical trial progress for RAS-mutated colorectal cancer.
Analysts maintain optimistic ratings with high price targets ($6-$12).
Revenue increased 60.93% YoY in Q4 2025.
Significant net income loss (-$7.22M in Q4
and declining EPS (-50% YoY).
Onvansertib approval pushed to 2030, delaying potential revenue streams.
Leadership changes and revenue decline of 13.2% for FY
No significant hedge fund or insider trading activity.
In Q4 2025, revenue increased by 60.93% YoY to $243,000, but net income dropped by -38.75% YoY to -$7.22M. EPS fell by -50% YoY to -$0.11. Gross margin remained stable at 100%. Despite revenue growth, the company's financials remain weak with substantial losses.
Analysts are optimistic about Cardiff Oncology's long-term potential. Piper Sandler lowered the price target to $6 but maintained an Overweight rating, citing sufficient cash to fund operations into Q1 2027. H.C. Wainwright views the recent selloff as an attractive entry point with a $10 price target, and Noble Capital initiated coverage with an Outperform rating and a $12 price target. However, the timeline for drug approval and clinical risks remain concerns.
